Teachers Retirement System of The State of Kentucky Has $4.58 Million Stock Position in Haemonetics Co. (NYSE:HAE)

Teachers Retirement System of The State of Kentucky boosted its position in shares of Haemonetics Co. (NYSE:HAE) by 25.6% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 53,651 shares of the medical instruments supplier’s stock after purchasing an additional 10,930 shares during the period. Teachers Retirement System of The State of Kentucky owned 0.11% of Haemonetics worth $4,579,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the company. Parkside Financial Bank & Trust boosted its position in Haemonetics by 17.4% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,054 shares of the medical instruments supplier’s stock valued at $90,000 after purchasing an additional 156 shares during the last quarter. Keene & Associates Inc. raised its holdings in Haemonetics by 3.1% during the fourth quarter. Keene & Associates Inc. now owns 8,780 shares of the medical instruments supplier’s stock valued at $751,000 after buying an additional 268 shares in the last quarter. Louisiana State Employees Retirement System raised its holdings in Haemonetics by 2.1% during the first quarter. Louisiana State Employees Retirement System now owns 14,600 shares of the medical instruments supplier’s stock valued at $1,246,000 after buying an additional 300 shares in the last quarter. State of Michigan Retirement System raised its holdings in Haemonetics by 2.5% during the first quarter. State of Michigan Retirement System now owns 12,474 shares of the medical instruments supplier’s stock valued at $1,065,000 after buying an additional 300 shares in the last quarter. Finally, Natixis Advisors L.P. raised its holdings in Haemonetics by 2.1% during the fourth quarter. Natixis Advisors L.P. now owns 15,819 shares of the medical instruments supplier’s stock valued at $1,352,000 after buying an additional 324 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Barrington Research raised their target price on Haemonetics from $105.00 to $107.00 and gave the company an “outperform” rating in a report on Friday, May 10th. JMP Securities raised their target price on Haemonetics from $115.00 to $125.00 and gave the company a “market outperform” rating in a report on Friday, May 10th. Finally, Needham & Company LLC upgraded Haemonetics from a “hold” rating to a “buy” rating and set a $112.00 target price on the stock in a report on Wednesday, June 12th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $109.50.

Insider Buying and Selling

In related news, insider Stewart W. Strong sold 733 shares of the business’s stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $96.04, for a total value of $70,397.32. Following the completion of the transaction, the insider now owns 15,608 shares in the company, valued at approximately $1,498,992.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider Stewart W. Strong sold 733 shares of the firm’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $96.04, for a total value of $70,397.32. Following the transaction, the insider now directly owns 15,608 shares in the company, valued at approximately $1,498,992.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Anila Lingamneni sold 2,305 shares of the firm’s stock in a transaction on Monday, May 6th. The stock was sold at an average price of $95.00, for a total value of $218,975.00. Following the completion of the transaction, the executive vice president now owns 12,295 shares in the company, valued at $1,168,025. The disclosure for this sale can be found here. Insiders sold 33,828 shares of company stock worth $3,031,095 in the last quarter. Insiders own 1.80% of the company’s stock.

Haemonetics Stock Performance

HAE stock traded down $0.28 during trading on Friday, reaching $89.85. 504,517 shares of the stock were exchanged, compared to its average volume of 401,314. Haemonetics Co. has a twelve month low of $70.74 and a twelve month high of $97.97. The company has a market capitalization of $4.58 billion, a P/E ratio of 39.20, a price-to-earnings-growth ratio of 1.64 and a beta of 0.29. The stock has a 50 day simple moving average of $86.93 and a 200-day simple moving average of $84.17. The company has a current ratio of 2.56, a quick ratio of 1.50 and a debt-to-equity ratio of 0.83.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, May 9th. The medical instruments supplier reported $0.90 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.02. The company had revenue of $343.00 million for the quarter, compared to the consensus estimate of $329.53 million. Haemonetics had a return on equity of 22.25% and a net margin of 8.98%. The company’s quarterly revenue was up 12.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.77 earnings per share. As a group, sell-side analysts anticipate that Haemonetics Co. will post 4.57 earnings per share for the current year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.